Journal DOI 10.68956/dyh5-kwte

Creative Commons source reading · Alzheimer’s disease and related dementias

Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies.

Jifa Zhang; Yinglu Zhang; Jiaxing Wang; Yilin Xia; Jiaxian Zhang; Lei Chen

Originally published in Signal transduction and targeted therapy · 2024-08-23

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

Alzheimer's disease (AD) stands as the predominant form of dementia, presenting significant and escalating global challenges. Its etiology is intricate and diverse, stemming from a combination of factors such as aging, genetics, and environment. Our current understanding of AD pathologies involves various hypotheses, such as the cholinergic, amyloid, tau protein, inflammatory, oxidative stress, metal ion, glutamate excitotoxicity, microbiota-gut-brain axis, and abnormal autophagy. Nonetheless, unraveling the interplay among these pathological aspects and pinpointing the primary initiators of AD require further elucidation and validation. In the past decades, most clinical drugs have been discontinued due to limited effectiveness or adverse effects. Presently, available drugs primarily offer symptomatic relief and often accompanied by undesirable side effects. However, recent approvals of aducanumab (1) and lecanemab (2) by the Food and Drug Administration (FDA) present the potential in disrease-modifying effects. Nevertheless, the long-term efficacy and safety of these drugs need further validation.

Conclusions and prospects

The current approaches to addressing AD focus on three main aspects: prevention, early diagnosis, and treatment. Managing modifiable risk factors provides a pathway for AD prevention, which may help reducing cognitive decline and the risk of AD. In early diagnosis, various biomarkers of CSF, blood, urine,610 saliva,611 and retina,612 may contribute to comprehensively reflecting the AD pathological process, serving as potential auxiliary tools that are more convenient, cost-effective, or less invasive.

Editorial reading guide

  • Was the evidence cross-sectional, longitudinal or experimental?
  • How did the authors account for age, disease stage and differences among participants?